Skip to content

Anika Therapeutics ANIK Cash Flow Statement

Q2 '26Q1 '26Q4 '25Q3 '25Q2 '25
-$3.31M+16.6%-$5.06M-3.8%$0+100%-$2.33M+92.2%-$3.97M-4,411%
$1.51M+17.6%$1.41M+1.7%$1.32M-15.5%$1.39M-25.2%$1.28M-26.0%
$1.83M-28.1%$6.64M+132%$2.46M+9.0%$2.22M-34.7%$2.55M-34.5%
-$684K-262%-$4.85M-3,628%$4.64M+193%$6.87M+37.0%-$189K+82.3%
$1.45M-1.2%$1.43M-49.3%$648K-50.4%$1.89M+55.2%$1.47M-56.9%
-$1.28M-$1.24M-174%-$1.73M+4.6%
$853K$8.69M+119%$5.51M-1.1%
-$701K-$10.35M-90.3%-$5.28M+1.4%-$13K+99.7%$0+100%
-$2.61M-1,178%-$16.46M-335%$4.82M+1,162%-$204K+96.5%
-$2.13M-28.8%-$6.28M-112%$3.99M$4.98M-$1.66M+63.0%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Anika Therapeutics generate?
Anika Therapeutics (ANIK) generated $6.0M in operating cash flow over the trailing twelve months.
What is Anika Therapeutics's free cash flow?
After $5.4M of capital expenditures, Anika Therapeutics's free cash flow was $562.0K over the trailing twelve months, up 105.1% year over year.
Where does Anika Therapeutics's cash flow data come from?
Every line is extracted from Anika Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.